<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107393</url>
  </required_header>
  <id_info>
    <org_study_id>TUGSM-UHA-BC03-01</org_study_id>
    <secondary_id>CDR0000380787</secondary_id>
    <nct_id>NCT00107393</nct_id>
  </id_info>
  <brief_title>Trastuzumab and Capecitabine in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Study of Trastuzumab (Herceptin) and Capecitabine (Xeloda) in Women With Taxanes and Anthracyclines Refractory Metastatic Breast Cancer and HER2 Over-Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tohoku University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as&#xD;
      capecitabine, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Giving trastuzumab together with capecitabine may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving trastuzumab together with&#xD;
      capecitabine works in treating women with metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the median survival time and 2-year survival rate in women with taxane- and&#xD;
           anthracycline-refractory HER2/neu-overexpressing metastatic breast cancer treated with&#xD;
           trastuzumab (Herceptin®) and capecitabine.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the progression-free survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the response rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the clinical benefit rate of this regimen in these patients.&#xD;
&#xD;
        -  Determine the safety profile of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to prior treatment&#xD;
      with trastuzumab (Herceptin®) (yes vs no), HER2/neu status (3+ by immunohistochemistry vs&#xD;
      positive by fluorescence in situ hybridization), and class of refractory disease (primary vs&#xD;
      secondary vs treatment discontinuation due to adverse events).&#xD;
&#xD;
      Patients receive oral capecitabine once daily on days 1-21 and trastuzumab IV on days 1, 8,&#xD;
      15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed for up to 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 75 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median survival and 2-year survival rate as measured by the Kaplan-Meier method 2 years after completion of study treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate as measured by Kaplan-Meier method 2 years after completion of study treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile as measured by the Kaplan-Meier method 2 years after completion of study treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
                    -  Patients with only bone metastases are not eligible&#xD;
&#xD;
          -  Refractory disease, defined as disease progression, drug-related adverse reaction, or&#xD;
             disease relapse during or within 12 months after completion of paclitaxel or docetaxel&#xD;
             AND doxorubicin or epirubicin administered in the neoadjuvant, adjuvant, or metastatic&#xD;
             setting&#xD;
&#xD;
               -  Total neoadjuvant or adjuvant taxane dose &gt; 700 mg/m^2 for paclitaxel or &gt; 240&#xD;
                  mg/m^2 for docetaxel&#xD;
&#xD;
               -  Total taxane dose &gt; 350 mg/m^2 for paclitaxel or &gt; 120 mg/m^2 for docetaxel in&#xD;
                  the metastatic setting&#xD;
&#xD;
               -  Total neoadjuvant or adjuvant anthracycline dose &gt; 240 mg/m^2 for doxorubicin or&#xD;
                  epirubicin&#xD;
&#xD;
               -  Total anthracycline dose &gt; 120 mg/m^2 for doxorubicin or epirubicin in the&#xD;
                  metastatic setting&#xD;
&#xD;
          -  HER2/neu overexpression&#xD;
&#xD;
               -  3+ by immunohistochemistry or positive by fluorescence in situ hybridization&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
          -  No pleural or pericardial effusion or ascites&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  20 to 75&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGOT or SGPT ≤ 2.0 times upper limit of normal (ULN) (&lt; 3.0 times ULN for patients&#xD;
             with liver metastases)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.2 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF &gt; 50%&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No interstitial pneumonia with pulmonary fibrosis&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No history of hypersensitivity reactions&#xD;
&#xD;
          -  No serious, uncontrolled infection&#xD;
&#xD;
          -  No other malignancy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior trastuzumab (Herceptin®) for metastatic disease allowed&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior capecitabine&#xD;
&#xD;
          -  At least 2 weeks since prior antimetabolites for metastatic disease&#xD;
&#xD;
          -  At least 4 weeks since prior alkylating agents, carcinostatic antibiotics, or other&#xD;
             carcinostatic agents&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 4 weeks since prior goserelin or leuprolide for metastatic disease&#xD;
&#xD;
          -  At least 2 weeks since prior oral endocrine agents for metastatic disease&#xD;
&#xD;
          -  No concurrent endocrine therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to target lesions&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy, including radiotherapy for brain metastases&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Concurrent bisphosphonates for bone metastases allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noriaki Ohuchi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tohoku University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kitakyushu Municipal Medical Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>802-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido Cancer Center</name>
      <address>
        <city>Hokkaido</city>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Marianna University School of Medicine</name>
      <address>
        <city>Kanagawa</city>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization - Osaka National Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Kosei Nenkin Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>553-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Graduate School of Medicine</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Graduate School of Medicine</name>
      <address>
        <city>Sendai</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's International Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakata Municipal Hospital</name>
      <address>
        <city>Yamagata</city>
        <zip>998-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Ishida T, Kiba T, Takeda M, Matsuyama K, Teramukai S, Ishiwata R, Masuda N, Takatsuka Y, Noguchi S, Ishioka C, Fukushima M, Ohuchi N. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemother Pharmacol. 2009 Jul;64(2):361-9. doi: 10.1007/s00280-008-0882-8. Epub 2008 Dec 12.</citation>
    <PMID>19082596</PMID>
  </results_reference>
  <verification_date>October 2006</verification_date>
  <study_first_submitted>April 5, 2005</study_first_submitted>
  <study_first_submitted_qc>April 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2005</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

